EZH2基因在膀胱移行细胞癌细胞株和癌组织标本中的表达及意义

目的 探讨EZH2基因在膀胱癌发生及进展中的作用. 方法 应用RT-PCR、蛋白质印迹及免疫细胞化学方法,以前列腺癌细胞株PC-3M作为阳性对照,检测EZH2基因在人膀胱移行细胞癌细胞株T24、EJ、MGH-U1、BIU-87中的表达;采用RT-PCR方法检测45例膀胱移行细胞癌和12例正常膀胱黏膜组织中EZH2基因表达情况.45例膀胱移行细胞癌中表浅性癌(Tis、Ta、T1)31例(68.9%),浸润性癌(T2～T4)14例(31.1%);病理分级G1 13例(28.9%),G2 21例(46.7%),G3 11例(24.4%). 结果 4种膀胱癌细胞株中均有EZH2基因表达.EZH2基因在膀胱移行细胞癌组织中的表达率(82.2%)明显高于正常膀胱黏膜(8.3%,P<0.05),在表浅性膀胱癌中的表达率为74.2%,浸润性膀胱癌中为100.0%,差异无统计学意义(P>0.05).EZH2基因在G1,G2和G3级肿瘤中的表达率分别为61.5%,85.7%和100.0%.随细胞分级程度升高.EZH2表达率有增加趋势,但差异无统计学意义(P>0.05). 结论 EZH2基因可能在膀胱癌的发生及进展中起重要作用,可能成为膀胱癌一个潜在的基因治疗靶点.

Expression of enhancer of zeste homolog 2 in transitional cell carcinoma of the bladder cell lines and tissues

Objective To study the expression of enhancer of zeste homolog 2 (EZH2) gene in transitional cell carcinoma (TCC) of the bladder celt lines, carcinoma tissues and normal bladder tis-sues and to evaluate the roles of EZH2 in the development and progression of bladder carcinoma. Methods RT-PCR, Western-blot and immunocytochemistry were used to analyze the expression of EZH2 of the bladder cell lines (T24, EJ, MGH-U1, BIU-87). The prostate cancer cell line PC-3M was used as an EZH2-positive cell line. EZH2 gene expressions in 45 cases of bladder carcinoma and 12 cases of normal bladder mueosa were detected by RT-PCR. Of cancer cases, 31 were superficial tumors and 14 were invasive tumors; 13 were G1, 21 were G2 and 11 were G3. Results EZH2 was detected in the 4 TCC cell lines. The EZH2 expression rate of TCC (82.2%) was significantly higher than that of normal bladder tissues (8.3%, P<0.05). The expression rate in superficial tumors was 74.2% and in invasive tumors was 100.0%, but there was no significant difference (P>0.05). The expression rates increased with tumor cell grade increase, but there was no significant difference (P> 0.05). Conclusions EZH2 could play an important role in the development and progression of blad-der carcinoma. It could be used as a potential gene therapy target of bladder cancer.